EverHint – Volatile High Beta – Top 3 Signals for Jun 26, 2026
What This Signal Is
High momentum stock screener for swing trading opportunities. Identifies stocks with strong momentum characteristics suitable for swing trading (1-4 week holds). Includes multiple variants: breakout, pullback, aggressive momentum, and volatile high-beta.
Entry Criteria:
- Strong RSI momentum (configurable thresholds)
- Volume surge above average
- Price momentum confirmation
- Minimum ADV: $25M+ (varies by variant)
- Earnings buffer: 7 days pre/post earnings
- Variant-specific filters applied
Holding period: 1-4 weeks | Risk level: Medium-High
Market Context
Equity markets are experiencing a mild pullback on June 26, 2026, with tech-heavy indices leading the decline as the Nasdaq sheds 0.60% compared to the Dow's more modest 0.09% dip. This divergence suggests a rotation away from growth-oriented names and toward more defensive positioning. Despite the broad index weakness, the VIX declining nearly 3% to 18.34 signals that traders are not particularly alarmed — volatility remains contained in a moderate range, which is a constructive backdrop for momentum swing strategies that rely on directional moves without excessive noise disrupting entries and exits.
A VIX in the high-teens typically supports measured intraday swings, offering enough price movement for momentum setups to develop without the erratic whipsawing seen in high-volatility regimes above 25. For swing traders, this environment favors holding positions over one to several days as trends have room to breathe. However, the slight risk-off tone across major indices warrants tighter risk management, as any unexpected uptick in volatility could compress the window for profitable momentum trades.
Healthcare emerging as the top sector for today's signals aligns well with the current market tone. When broader markets soften and risk appetite cools, healthcare tends to attract defensive capital flows, providing relative strength that momentum strategies can exploit. Sector rotation into defensive areas like healthcare during periods of index-level weakness often produces cleaner, more sustained momentum setups compared to cyclical sectors, making it a favorable hunting ground for swing signals in today's conditions.
📊 Signals (3 of 3 total)
Ranked by composite momentum score (higher = stronger momentum)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | MANE | Veradermics, Incorporated | Healthcare | $126.89 | 1.00 | — | $5.3B |
| 2 | PII | Polaris Inc. | Consumer Cyclical | $72.56 | 0.50 | — | $4.1B |
| 3 | CNTA | Centessa Pharmaceutica... | Healthcare | $40.50 | 0.00 | -$23,810 | $6.3B |
Field Notes
Sector concentration: Healthcare (2), Consumer Cyclical (1)
Insider selling: CNTA (Centessa Pharmaceuticals plc, -$23,810)
Data coverage: 66.7% insider, 0.0% congressional, 0.0% earnings, 66.7% news
Peer Analysis
CNTA (Centessa Pharmaceuticals plc): Leads 5 peers: APGE ($132.55), XENE ($59.74), AAPG ($16.77), RARE ($30.77), CELC ($99.95)
MANE (Veradermics, Incorporated): Leads 5 peers: ABEO ($5.61), DRMA ($1.29), HELP ($6.48), OVID ($2.55), PLYX ($2.40)
PII (Polaris Inc.): Leads 5 peers: BC ($87.08), HOG ($25.19), RUSHA ($72.78), WHR ($38.98), PVH ($74.38)
Recent Headlines
CNTA (Centessa Pharmaceuticals plc)
- Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
MANE (Veradermics, Incorporated)
- Biotech ETF Index Surges 10% After Rebalance
- Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.